Stelara was first approved for psoriasis 10 years ago, and follow-up indications in psoriatic arthritis and Crohn’s disease have kept the drug growing at a healthy pace to reach more than $5 ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...

Darzalex, which treats multiple myeloma, has become the first Johnson & Johnson drug to ever top $3 billion in quarterly ...

The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...

Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in ...

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

What Growth Drivers Underpin the Stelara Ustekinumab Market? The rise in prevalence of psoriasis patients is a significant propellant for the growth of the Stelara ustekinumab market. Psoriasis ...

Johnson & Johnson ( JNJ, Financial) stock saw a 2% decline on Wednesday following a robust fourth-quarter earnings report that surpassed Wall Street expectations. The healthcare giant, recently ...

Johnson & Johnson , fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular , reported fourth-quarter ...